Table 1.
Patient characteristics at baseline
| Total (N = 149) | No/mild fatigue < 45 (N = 82) | Strong fatigue > 45 (N = 67) | P value | |
|---|---|---|---|---|
| Sex | ns | |||
| Male | 80 (54%) | 43 | 37 | |
| Female | 69 (46%) | 39 | 30 | |
| Age | ns | |||
| < 70 years | 4 (3%) | 1 | 3 | |
| 70–79 years | 87 (58%) | 45 | 42 | |
| 80–89 years | 53 (36%) | 33 | 20 | |
| > 90 years | 5 (3%) | 3 | 2 | |
| Entities | ns | |||
| Myelodysplastic syndromes | 43 (29%) | 29 | 14 | |
| Acute myeloid leukemia | 48 (32%) | 22 | 26 | |
| Myeloproliferative neoplasmsa | 10 (7%) | 5 | 5 | |
| Non-Hodgkin’s lymphoma—indolentb | 13 (9%) | 7 | 6 | |
| Non-Hodgkin’s lymphoma—aggressivec | 33 (22%) | 19 | 14 | |
| Multiple myeloma | 2 (1%) | 0 | 2 | |
| Geriatric impairments in MGA | 0.001 | |||
| </= 3 | 95 (64%) | 65 | 30 | |
| > 3 | 54 (36%) | 17 | 37 | |
| Survival | 0.014 | |||
| Alive | 34 (29%) | 25 | 9 | |
| Dead | 115 (71%) | 57 | 58 | |
| Serum ferritin | N = 145 | ns | ||
| < 400 μg/l | 79 (54%) | 47 | 32 | |
| > 400 μg/l | 66 (46%) | 35 | 31 |
aMyeloproliferative neoplasms included chronic myelomonocytic leukemia, chronic myeloid leukemia, and myelodysplastic syndromes—myeloproliferative neoplasm unclassifiable
bNon-Hodgkin’s lymphoma-indolent included B cell chronic lymphocytic leukemia, small lymphocytic non-Hodgkin’s lymphoma, Morbus Waldenström, low-grade mucosa-associated lymphoid tissue non-Hodgkin’s lymphoma, and hairy cell leukemia
cNon-Hodgkin’s lymphoma-aggressive included diffuse large B cell lymphoma, mantle cell lymphoma, prolymphocytic leukemia, and T cell non-Hodgkin’s lymphoma
MGA multidimensional geriatric assessment, ns not significant; P values < 0.05 were considered significant; P values were calculated using Chi-square tests